Tech Company Financing Transactions

Inspirna Funding Round

Sands Capital Management, Vivo Capital and Dreavent 6 participated in a $50 million Series D venture round for Inspirna. The round was announced by the company on 7/11/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

310 East 67th St. 1-12
New York, NY 10065
USA

Phone

(646) 856-9261

Website

www.inspirna.com

Email Address

[email protected]

Overview

Inspirna (formerly Rgenix) is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Masoud Tavazoie

        

Chief Operating Officer

David Darst

        

Vice President

Stephen Wald

        

VP - Bus. Development

Foster Gonsalves

        

VP - Finance

Corey Sohmer

        

VP - R & D

Isabel Kurth

        

VP - Regulatory Affairs

Michael Szarek

        

Browse more venture capital transactions:

Prev: 7/11/2022: Halo Labs venture capital transaction
Next: 7/11/2022: Byzantion venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary